Switch to
More onapp

Bal Pharma Ltd

BALPHARMA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹136 cr, stock is ranked 2,019
Moderate RiskStock is 2.84x as volatile as Nifty
86.700.50 (-0.57%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹136 cr, stock is ranked 2,019
Moderate RiskStock is 2.84x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
24.44
PB RatioPB Ratio
2.34
Dividend YieldDiv. Yield
1.08%
Sector PESector PE
35.90
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bal Pharma Limited is a pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). The Company specializes in prescription drugs, generic, over the counter (OTC) products, intravenous infusion and bulk actives. It offers a range of APIs, which includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, and diuretic, acne treatment. It also manufactures and supplies natural medicines in the segment of bulk actives, formulations, generics and herbals. Its finished formulation products covers dosage forms, such as tablets, capsules, syrups, suspensions, IV infusions, Ophthalmic, creams and ointments. The Company offers a range of natural medicine, which includes ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP.

Investor PresentationView older 

Sep 7, 2022

PDF
View Older Presentations

Financial TrendFinancial statements 

2019202020212022226.02172.94251.67286.363.80-12.224.745.60
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 2.43%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Resignation 
Announced OnNov 24, 2022

Bal Pharma Limited has informed the Exchange about resignation of G Rengarajan as Chief Financial Officer of the company w.e.f. 24-Nov-2022 | Download

Bal Pharma Limited has informed the Exchange about resignation of G Rengarajan as Chief Financial Officer of the company w.e.f. 24-Nov-2022 | Download

Extra Ordinary Meeting 
Announced OnNov 18, 2022

Bal Pharma Limited has informed the Exchange about Notice of Extra Ordinary General Meeting to be held on 14-Dec-2022 | Download

Bal Pharma Limited has informed the Exchange about Notice of Extra Ordinary General Meeting to be held on 14-Dec-2022 | Download

Cash Dividend 
Ex. DateSep 13, 2022

Final • Div/Share: ₹ 1

See all events